September 19, 2024

Dosing of the first patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Year

2024

Assets in this page

Download assets

  • pdf file

    Current Report ESPI 29/2024

    Download